Financhill
Buy
57

GMAB Quote, Financials, Valuation and Earnings

Last price:
$22.87
Seasonality move :
4.05%
Day range:
$22.70 - $23.08
52-week range:
$17.24 - $28.56
Dividend yield:
0%
P/E ratio:
13.57x
P/S ratio:
4.78x
P/B ratio:
2.65x
Volume:
1.1M
Avg. volume:
1.4M
1-year change:
-13.59%
Market cap:
$14.1B
Revenue:
$3B
EPS (TTM):
$1.68

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GMAB
Genmab AS
$759.6M $0.23 17.19% 7.82% $29.69
ASND
Ascendis Pharma AS
$107.9M -$1.71 296.68% -21.04% $229.05
EVAX
Evaxion AS
$60K -$0.71 -100% -90.33% $13.25
GLTO
Galecto
-- -$2.82 -- -51.46% $6.00
IOBT
IO Biotech
-- -$0.23 -- -3.23% $9.50
NVO
Novo Nordisk AS
$11.9B $0.92 19.3% 36.74% $91.54
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GMAB
Genmab AS
$22.82 $29.69 $14.1B 13.57x $0.00 0% 4.78x
ASND
Ascendis Pharma AS
$170.80 $229.05 $10.3B -- $0.00 0% 25.44x
EVAX
Evaxion AS
$2.77 $13.25 $17.5M -- $0.00 0% 1.83x
GLTO
Galecto
$3.35 $6.00 $4.4M -- $0.00 0% --
IOBT
IO Biotech
$1.35 $9.50 $88.9M -- $0.00 0% --
NVO
Novo Nordisk AS
$79.83 $91.54 $354.7B 23.64x $1.14 2.08% 8.16x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GMAB
Genmab AS
-- -0.032 -- 5.32x
ASND
Ascendis Pharma AS
128.87% 0.036 9.75% 0.67x
EVAX
Evaxion AS
-- 2.568 -- 2.80x
GLTO
Galecto
-- 1.946 -- --
IOBT
IO Biotech
-- -0.443 -- --
NVO
Novo Nordisk AS
46.15% 1.812 5.59% 0.54x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GMAB
Genmab AS
$673M $188M 22.23% 22.23% 34.83% $257M
ASND
Ascendis Pharma AS
$87.8M -$106M -59.13% -880.05% -48.32% -$15.8M
EVAX
Evaxion AS
-- -$3.9M -238.97% -- -54.59% --
GLTO
Galecto
-- -$2.6M -- -- -- -$2.4M
IOBT
IO Biotech
-- -$22.6M -- -- -- -$23.1M
NVO
Novo Nordisk AS
$9.2B $5.5B 53.78% 84.88% 54.06% $1.4B

Genmab AS vs. Competitors

  • Which has Higher Returns GMAB or ASND?

    Ascendis Pharma AS has a net margin of 27.27% compared to Genmab AS's net margin of -93.73%. Genmab AS's return on equity of 22.23% beat Ascendis Pharma AS's return on equity of -880.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMAB
    Genmab AS
    94.13% $0.31 $5.3B
    ASND
    Ascendis Pharma AS
    82.65% -$1.66 $711.6M
  • What do Analysts Say About GMAB or ASND?

    Genmab AS has a consensus price target of $29.69, signalling upside risk potential of 30.09%. On the other hand Ascendis Pharma AS has an analysts' consensus of $229.05 which suggests that it could grow by 34.11%. Given that Ascendis Pharma AS has higher upside potential than Genmab AS, analysts believe Ascendis Pharma AS is more attractive than Genmab AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMAB
    Genmab AS
    4 4 0
    ASND
    Ascendis Pharma AS
    12 0 0
  • Is GMAB or ASND More Risky?

    Genmab AS has a beta of 0.956, which suggesting that the stock is 4.415% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.446%.

  • Which is a Better Dividend Stock GMAB or ASND?

    Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab AS pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMAB or ASND?

    Genmab AS quarterly revenues are $715M, which are larger than Ascendis Pharma AS quarterly revenues of $106.2M. Genmab AS's net income of $195M is higher than Ascendis Pharma AS's net income of -$99.6M. Notably, Genmab AS's price-to-earnings ratio is 13.57x while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.78x versus 25.44x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMAB
    Genmab AS
    4.78x 13.57x $715M $195M
    ASND
    Ascendis Pharma AS
    25.44x -- $106.2M -$99.6M
  • Which has Higher Returns GMAB or EVAX?

    Evaxion AS has a net margin of 27.27% compared to Genmab AS's net margin of -64.14%. Genmab AS's return on equity of 22.23% beat Evaxion AS's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GMAB
    Genmab AS
    94.13% $0.31 $5.3B
    EVAX
    Evaxion AS
    -- -$0.50 $74K
  • What do Analysts Say About GMAB or EVAX?

    Genmab AS has a consensus price target of $29.69, signalling upside risk potential of 30.09%. On the other hand Evaxion AS has an analysts' consensus of $13.25 which suggests that it could grow by 378.34%. Given that Evaxion AS has higher upside potential than Genmab AS, analysts believe Evaxion AS is more attractive than Genmab AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMAB
    Genmab AS
    4 4 0
    EVAX
    Evaxion AS
    1 0 0
  • Is GMAB or EVAX More Risky?

    Genmab AS has a beta of 0.956, which suggesting that the stock is 4.415% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock GMAB or EVAX?

    Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab AS pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMAB or EVAX?

    Genmab AS quarterly revenues are $715M, which are larger than Evaxion AS quarterly revenues of $3M. Genmab AS's net income of $195M is higher than Evaxion AS's net income of -$1.6M. Notably, Genmab AS's price-to-earnings ratio is 13.57x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.78x versus 1.83x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMAB
    Genmab AS
    4.78x 13.57x $715M $195M
    EVAX
    Evaxion AS
    1.83x -- $3M -$1.6M
  • Which has Higher Returns GMAB or GLTO?

    Galecto has a net margin of 27.27% compared to Genmab AS's net margin of --. Genmab AS's return on equity of 22.23% beat Galecto's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GMAB
    Genmab AS
    94.13% $0.31 $5.3B
    GLTO
    Galecto
    -- -$1.92 --
  • What do Analysts Say About GMAB or GLTO?

    Genmab AS has a consensus price target of $29.69, signalling upside risk potential of 30.09%. On the other hand Galecto has an analysts' consensus of $6.00 which suggests that it could grow by 79.11%. Given that Galecto has higher upside potential than Genmab AS, analysts believe Galecto is more attractive than Genmab AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMAB
    Genmab AS
    4 4 0
    GLTO
    Galecto
    0 1 0
  • Is GMAB or GLTO More Risky?

    Genmab AS has a beta of 0.956, which suggesting that the stock is 4.415% less volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock GMAB or GLTO?

    Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab AS pays -- of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMAB or GLTO?

    Genmab AS quarterly revenues are $715M, which are larger than Galecto quarterly revenues of --. Genmab AS's net income of $195M is higher than Galecto's net income of -$2.5M. Notably, Genmab AS's price-to-earnings ratio is 13.57x while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.78x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMAB
    Genmab AS
    4.78x 13.57x $715M $195M
    GLTO
    Galecto
    -- -- -- -$2.5M
  • Which has Higher Returns GMAB or IOBT?

    IO Biotech has a net margin of 27.27% compared to Genmab AS's net margin of --. Genmab AS's return on equity of 22.23% beat IO Biotech's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GMAB
    Genmab AS
    94.13% $0.31 $5.3B
    IOBT
    IO Biotech
    -- -$0.34 --
  • What do Analysts Say About GMAB or IOBT?

    Genmab AS has a consensus price target of $29.69, signalling upside risk potential of 30.09%. On the other hand IO Biotech has an analysts' consensus of $9.50 which suggests that it could grow by 603.7%. Given that IO Biotech has higher upside potential than Genmab AS, analysts believe IO Biotech is more attractive than Genmab AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMAB
    Genmab AS
    4 4 0
    IOBT
    IO Biotech
    2 0 0
  • Is GMAB or IOBT More Risky?

    Genmab AS has a beta of 0.956, which suggesting that the stock is 4.415% less volatile than S&P 500. In comparison IO Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock GMAB or IOBT?

    Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IO Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab AS pays -- of its earnings as a dividend. IO Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMAB or IOBT?

    Genmab AS quarterly revenues are $715M, which are larger than IO Biotech quarterly revenues of --. Genmab AS's net income of $195M is higher than IO Biotech's net income of -$22.4M. Notably, Genmab AS's price-to-earnings ratio is 13.57x while IO Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.78x versus -- for IO Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMAB
    Genmab AS
    4.78x 13.57x $715M $195M
    IOBT
    IO Biotech
    -- -- -- -$22.4M
  • Which has Higher Returns GMAB or NVO?

    Novo Nordisk AS has a net margin of 27.27% compared to Genmab AS's net margin of 37.18%. Genmab AS's return on equity of 22.23% beat Novo Nordisk AS's return on equity of 84.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMAB
    Genmab AS
    94.13% $0.31 $5.3B
    NVO
    Novo Nordisk AS
    83.49% $0.92 $37.3B
  • What do Analysts Say About GMAB or NVO?

    Genmab AS has a consensus price target of $29.69, signalling upside risk potential of 30.09%. On the other hand Novo Nordisk AS has an analysts' consensus of $91.54 which suggests that it could grow by 14.61%. Given that Genmab AS has higher upside potential than Novo Nordisk AS, analysts believe Genmab AS is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMAB
    Genmab AS
    4 4 0
    NVO
    Novo Nordisk AS
    4 5 1
  • Is GMAB or NVO More Risky?

    Genmab AS has a beta of 0.956, which suggesting that the stock is 4.415% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.662, suggesting its less volatile than the S&P 500 by 33.759%.

  • Which is a Better Dividend Stock GMAB or NVO?

    Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.08% to investors and pays a quarterly dividend of $1.14 per share. Genmab AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GMAB or NVO?

    Genmab AS quarterly revenues are $715M, which are smaller than Novo Nordisk AS quarterly revenues of $11B. Genmab AS's net income of $195M is lower than Novo Nordisk AS's net income of $4.1B. Notably, Genmab AS's price-to-earnings ratio is 13.57x while Novo Nordisk AS's PE ratio is 23.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.78x versus 8.16x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMAB
    Genmab AS
    4.78x 13.57x $715M $195M
    NVO
    Novo Nordisk AS
    8.16x 23.64x $11B $4.1B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Palantir Crash?
Will Palantir Crash?

AI and data analytics software major Palantir (NASDAQ:PLTR) has been…

Is Target’s Dividend Worth Buying?
Is Target’s Dividend Worth Buying?

Retail giant Target (NYSE:TGT) has been through an extremely volatile…

Where Will AST SpaceMobile Be In 5 Years?
Where Will AST SpaceMobile Be In 5 Years?

Ever tried to send a text from the Nevada desert…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 48x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Sell
11
VEON alert for Jun 16

VEON [VEON] is up 4.61% over the past day.

Buy
74
DAVE alert for Jun 16

Dave [DAVE] is up 3.92% over the past day.

Buy
54
DAR alert for Jun 16

Darling Ingredients [DAR] is up 7.19% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock